Minimally Invasive Gastrointestinal (GI) Surgical Systems Market

Market Overview

The global Minimally Invasive Gastrointestinal Surgical Systems Market was valued at approximately USD 8.1 billion in 2024 and is projected to reach USD 14.7 billion by 2033, growing at a CAGR of 6.8% during the forecast period (2025–2033).

Minimally invasive gastrointestinal surgical systems allow for diagnostic and therapeutic procedures in the digestive tract through small incisions with using specialized tools, endoscopes, and frequently using some robotic assistance. These systems are helping surgeons carry out complex surgeries such as colectomy, gastrectomy, and bariatric surgeries with better precision, less trauma, and quicker recovery time. These systems are reducing patient discomfort, blood loss, and hospital stays and transforming the delivery of care in gastrointestinal procedure domains. The market is being fueled by increased incidence of gastrointestinal disorders, the shift toward outpatient surgery or laparoscopic surgery in place of traditional open surgery, advancements in robotic-assisted surgery and greater uptake in both developed and developing healthcare delivery models.

Market Dynamics

Market Drivers

Rising Incidence of Gastrointestinal Disorders and Colorectal Cancers

The increasing prevalence of gastrointestinal disorders, including colorectal cancer, gastroesophageal reflux disease (GERD), Crohn’s disease, and peptic ulcers, is a primary factor driving the demand for minimally invasive GI surgical systems. According to the World Health Organization (WHO), colorectal cancer ranks as the third most common cancer globally and the second leading cause of cancer-related deaths, with approximately 1.9 million new cases reported in 2022 alone.

The rise in early screening programs and heightened patient awareness has led to earlier detection, making patients more eligible for minimally invasive procedures. Minimally invasive techniques, including laparoscopic and endoscopic surgeries, are increasingly preferred due to their ability to reduce surgical trauma, minimize postoperative complications, and shorten hospital stays.

For instance, Intuitive Surgical’s da Vinci Xi system and Medtronic’s Hugo™ robotic-assisted surgery platform are now routinely used in GI surgeries, including colectomies and fundoplications. These tools offer superior visualization, dexterity, and precision, crucial for complex GI procedures. Additionally, the global rise in obesity and associated GI complications has led to a surge in bariatric surgeries, further propelling the adoption of advanced surgical systems.

Technological Advancements in Robotic and Endoscopic Surgery Systems

Rapid technological innovation has revolutionized the minimally invasive gastrointestinal surgical systems market. Advancements in robotic-assisted platforms, AI-guided surgical navigation, miniaturized instruments, and 4K and 3D endoscopic visualization have significantly enhanced procedural accuracy, safety, and outcomes.

These innovations enable surgeons to perform highly precise dissections and suturing in narrow anatomical spaces of the GI tract. For example, in 2023, Olympus Corporation launched its EVIS X1™ endoscopy system, which integrates AI-powered detection and enhanced image clarity for improved GI cancer screening and diagnosis. Similarly, Johnson & Johnson’s Ottava™ robotic system—expected to enter clinical trials soon—aims to compete with existing robotic systems in gastrointestinal surgeries with a smaller footprint and integrated imaging.

These systems allow for reduced intraoperative blood loss and faster patient recovery, making them attractive to both providers and patients. Moreover, global healthcare investment in surgical infrastructure is rising. According to the World Bank, healthcare spending as a share of GDP has increased consistently across high-income countries, fueling capital investments in cutting-edge surgical suites.

Hospitals across China, India, and the UAE are incorporating robotic surgical systems into standard practice as part of modernization initiatives. This confluence of innovation, improved patient outcomes, and health system readiness continues to boost market penetration of advanced GI surgical systems.

Market Restraints

High Cost of Minimally Invasive GI Surgical Systems and Procedures

The exorbitant cost of advanced surgical equipment, robotic systems, and training on any procedures is one of the key restraints restricting the growth of the market for minimally invasive gastroenterological surgical systems. The typical cost of robotic-assisted surgical platforms commonly used in the USD 1.5 million to USD 2.5 million range per unit alone, including yearly costs of over USD 100,000 for maintenance, consumables, disposable instruments, etc., creates an immense burden when outfitting small to mid-sized hospitals, particularly in developing countries with a limited budget for health care.

Also, per case costs associated with minimally invasive and robotic gastrointestinal surgical procedures (including robotic-assisted surgical procedures) are typically considerably higher than the cost of treatments for open surgery procedures. Notably, a study published in the Journal of the American Medical Association (JAMA) indicated that robotic colorectal surgery costs approximately USD 3,000–5,000 more per case than for standard laparoscopic procedures.

Increased costs stem primarily from longer procedure times associated with robotic surgeries (due to the increased steps per procedures and longer operational time), and the expensive reusable robotic and laparoscopic surgical instruments. In addition to the availability of expensive examination and procedural equipment, access to trained surgeons with proficiency in robotics and endoscopic techniques has limited the penetration of these technologies in the marketplace to date.

Many organizations wish to deliver comprehensive training programs for new CAD/CAM technology, but time, resources, and persuasion to use new technologies are frequently in unfriendly terms.  These combined factors create disparities in access to advanced surgical systems, especially in rural or underfunded regions, ultimately restraining the overall growth of the market.

Segmental Analysis

The Minimally Invasive Gastrointestinal Surgical Systems Market is segmented by product type, by application and end-user. Each segment plays a vital role in enhancing surgical precision, reducing patient recovery time, and improving clinical outcomes in gastrointestinal procedures.

By Product Type

In 2024, laparoscopic surgical instruments accounted for the largest market share of 38.2%, with the widespread usage of laparoscopic techniques in the execution of procedures such as appendectomies, hernia repairs, and bariatric surgeries leading these instruments—including trocars and the various types of scissors and graspers offered by instrument manufacturers—with strong cost-effectiveness and adoption in both high- and middle-income regions.

Robotic-assisted surgical systems are projected to grow the fastest in the forecast period, as we can expect increasing adoption in more complex gastrointestinal procedures such as colectomies and gastric bypass surgeries. The increasing installations of systems marketed by both Intuitive Surgical and Medtronic, such as the da Vinci and Hugo™ RAS systems, are anticipated to continue to fuel growth, especially in tertiary-care facilities.

The innovations in robotic-assisted surgery, including increasingly sophisticated technology like 3D visualization and tremors that filter out tremors when surgeons preserve natural motions, will offer adequate incentive for surgeons and patients to explore alternatives in robotic-assisted surgeries. Endoscopic devices are expanding.

This procedure category is gaining significant traction in recent years, especially for early-stage gastrointestinal cancers in diagnoses and early-stage minimally invasive therapeutic interventions. With expanding programs in colorectal cancer screening and growing adoption of AI-assisted endoscopy platforms like Olympus’ EVIS X1™ system, this market segment is likely to continue experiencing significant market growth in the coming years.

By End-User

Hospitals are presently the leading market segment for minimally invasive GI surgical systems and are expected to hold approximately 61.5% of the market share in 2024. Robotic and laparoscopic systems are mainly implemented in large hospitals and academic medical centers which have the advantages of wider operational capital budgets, an abundance of surgical staff, and integrated surgical suites.

In addition, segment growth can be linked to the increasing volume of GI surgeries performed in hospitals. Ambulatory Surgical Centers (ASC) is demonstrating fast growth, which can be attributed to the shift toward outpatient GI surgeries, mainly laparoscopic cholecystectomies and endoscopic polyp removals.

ASCs typically provide quicker patient turnover, lower procedural costs, and fewer hospital days when pursuing elective minimally invasive GI procedures. Specialty Clinics and research institutions are seeing a limited adoption of minimally invasive technologies due to their use of experimental therapies and initial diagnostics or procedures. The demand on these end-users should also see slow to moderate increases as specialized care and clinical trials expand.

By Application 

Colorectal surgery had the largest share (34.7% in 2024) due to incresing colorectal cancer cases that have driven global increases in laparoscopic and robotic colectomies by surgeons. Bariatric surgery is the fastest-growing application, driven by the global obesity epidemic, and recent demands for less invasive methods for gastric bypass and sleeve gastrectomy.

Anti-reflux surgery continues to grow steadily as the prevalence of gastroesophageal reflux disease (GERD) is significant and laparoscopic fundoplication techniques are becoming more favoured. Cholecystectomy remains one of the largest source of procedural volume as laparoscopic removal of the gall bladder is performed by surgeons worldwide.

Appendectomy remains in strong demand, especially in emergency departments, and employed laparoscopic methods as quick recovery is key. Other Applications such as gastrectomy, pancreatectomy, and GI tumor removal are also growing due to advances in robotic surgery and expanding utilization in more complex procedures.

Regional Analysis

North America

In 2024, North America will continue to account for the largest market share at 41.2% due to several factors like robust healthcare systems, higher procedural volumes, and acceptance of performing robotic and laparoscopic GI surgery as an alternative procedure.

In North America, the United States, specifically, performs a great deal of minimally invasive colorectal, bariatric, and anti-reflux surgeries. The presence of leading players like Intuitive Surgical, Medtronic, and Johnson & Johnson have favorable reimbursement policies and training programs for robotic surgeons, which will ensure that it remains a dominant market.

Europe

Europe has a prominent market share with important contributions expected from Germany, France, Italy, and the United Kingdom. Like North America, the European region continues to benefit from its deteriorating elders and a disturbing increase of colorectal cancer and GI disorders linked with obesity.

According to Eurostat, laparoscopic appendectomies and cholecystectomies have likely become the norm in several EU nations. The increase in advanced endoscopy systems and surgical robots in countries like Netherlands and Sweden could benefit the market.

Asia Pacific

Asia Pacific is the fastest growing regional market with a projected compound annual growth rate (CAGR) of 8.1% over the estimate. This growth is spearheaded by improved healthcare spending on public and private sectors, rapid urbanization, and rapid adoption of minimally invasive practices in countries like China, India, Japan, and South Korea governments’ task refers to modernize infrastructure for surgeries as incidences of GI cancers and obesity grow. Countries like Japan are pioneering in endoscopic procedures and China is rapidly deploying robotic surgical systems in tier-1 and tier-2 hospitals. 

Latin America and Middle East & Africa

Latin America and Middle East & Africa are consistently growing as public awareness of minimally invasive GI procedure increases and growth in public and private healthcare investments for access to laparoscopic and endoscopic technologies take shape.

Some countries like Brazil, Mexico, Saudi Arabia, and UAE are experiencing greater opportunities and awareness of laparoscopic and endoscopic technologies however issues like limited surgical talent, accessibility, and economic factors are still significant restrictions to full scale adoption, especially in Sub- Saharan Africa and parts of Central America.

Recent Development

1. May 2025: EndoQuest Robotics started clinical trials for its robotic system aimed at minimally invasive colorectal lesion removal.
2. April 2024: CMR Surgical upgraded its Versius robotic system with advanced imaging for better visualization during GI surgeries. 
3. October 2023: Olympus launched the EVIS X1™ endoscopy system, offering enhanced imaging technologies for GI procedures.